Genetic Carrier and Prenatal

	ming nequ	71332311 271322		
PATIENT INFORMATION				
Biolog	ical Sex			
Last Name M.I. Femal	e Male	Account Number Account Name		
First Name	C IVIAIC	Account Number		
Street Address	Apt #	City State 2	Zip Code	
City State Zi	p Code	Phone REFERRING PHYSICIAN		
	-	SAMPLE COLLECTION — (Complete A, B, and C)		
Date of Birth Medical Record # Patient Pho	ne #	A. Collection Date (MM/DD/YYYY):		
PAYMENT AND INSURANCE		B. Collection Time: C. Write patient's full name and date of birth on all tubes		
Self-Pay Medicaid Client Bill Bill Insurance Attachcopy of CLINICIAN SIGNATURE				
fro	nt and back of surance card	I will supply information to the patient regarding genetic testing, includin collection, use, retention, maintenance, and disclosure of the patient's samp of the genetic testing; and the benefits, risks, and limitations of the laborate and I will answer any of the patient's questions. I understand that the patient in consent for genetic testing to be performed. Any testing ordered is medically diagnosis or detection of disease, illness, impairment, symptom, syndrome the results will be used in the medical management and treatment decisio Physicians (or other individuals authorized by law to order tests) she tests that are medically necessary for the diagnosis or treatment of the	g: the manner of ble and the results bry test requested;	
		and I Will answer any of the patient's questions. I understand that the patient in consent for genetic testing to be performed. Any testing ordered is medically diagnosis or detection of disease, illness, impairment, symptom, syndrome the results will be used in the medical management and treatment decision.	nust give voluntary necessary for the on disorder, and ons for the patient.	
Subscriber Name ID #			ould only order patient.	
Group # Preauthorization	า #	Clinician Signature Da	ate	
PATIENT SIGNATURE FOR INFORMED CONSENT AND FINANCIAL RESPONSIBILITY				
collect, obtain, use, maintain, and retain a sample and the results of the testing for that purpose. I authorize the laboratory to disclose my medical information, including the results of my genetic testing, to the ordering clinician or healthcare provider for treatment purposes; Metis Genetics, LLC for purposes of genetic counseling when appropriate; and my health plan/insurance carrier and its authorized representatives as necessary for reimbursement unless otherwise indicated. I have had the opportunity to ask questions and discuss the capabilities, limitations, and		understand that I am responsible for any applicable copayment, coinsurance is specified by my health plan, including any costs relating to out-of-network on non-authorized services. I understand that Sonic and its affiliates will bill is required by my insurer, and in accordance with its policies, unless of applicable, I authorize Sonic to appeal any coverage denial made by mehalf. I understand to direct all cost estimates and coverage inquiries to romuninsured, to Sonic and its affiliates. I further authorize my health plan/instructly pay Sonic and its affiliates for services rendered. I understand that I may portions of this test not covered by my insurance. New York and Nevada le a separate consent form(s).	ork, non-covered, il my health plan herwise notified. ny insurer on my my insurer or, if I surance carrier to ay be responsible	
I accept full financial responsibility for any payment obligation associated with my test(s).		Patient Signature Date		
Non-Invasive Prenatal Screening (NIPS) Collect ONE Streening (NIPS) Singletons Only Fetal Sex Not Reported	eck tube G	Genetic Carrier Screening (CS) Collect TWO EDTA purp	ole-top tubes/test	
Please select ONLY ONE of the below test options If twins, only test code W907 or W906 is appropriate. With Fetal Sex Without Fetal Sex W905 NIPS w/ SCA ¹⁺ (Trisomies 21, 18, 13, w/ Sex Chromosome Aneuploidies) W907 NIPS, Twin ⁺ (Trisomies 21, 18, 13) W913 NIPS+ w/ Microdeletions 1+> (Trisomies 21, 18, 13, w/ Sex Chromosome Aneuploidies and Microdeletions 21, 18, 13, w/ Sex Chromosome Aneuploidies and Microdeletions 21, 18, 13, w/ Microdeletions) W915 NIPS+ w/ Microdeletions (Trisomies 21, 18, 13, w/ Microdeletions)	euploidies)	DE2720 Hemoglobin Electrophoresis** W139 CF 139 * W199 Fragile X Screen W7 Reflex Methylation** W220 SMA @# W801 Basic Trio, Female** (CF139, SMA) W802 Basic Duo, Female/Male* (CF139, SMA) W802 Memoglobin Electrophoresis** W557 Ashkenazi Jewish Panel, Male* W558 Ashkenazi Jewish Panel, Male* W559 Classic Panel, Female (24 genested) W560 Classic Panel, Male (22 genested) W555 Complete Panel, Female (157) W556 Complete Panel, Male (147 genested) Other Code:	(37 genes) nes) ^{+>} s) ⁺ 7 genes) ^{+>}	
Other Code:	C	CS Clinical Information (Required)		
NIPS Clinical Information (Required)		Patient Ethnicity: African American (AA) Caucasian (W) Hispanic (H)		
Number of Fetuses: (S)ingleton (T)wins Maternal Weight (lbs): Estimated Date of Delivery (EDD): // Maternal Height (in): IVF Pregnancy: Y N Patient/donor egg retrieval age: years NIPS Commonly Utilized ICD Codes (Required)		Asian (AS) Jewish (Ashkenazi) (J) Other (O): Not Specified (NS) Indication: Abnormal US (US) Egg/Sperm Donor (DO) Consanguinity (CO) Infertility (IN) Partner Known Carrier (PC) Patient Known Carrier (PT) Family History (HX)		
O09.291 Other poor reproductive or obstetric history, 1st tri O29.511 Elderly primigravida, 1st tri O29.512 Elderly primigravida and tri O234.81 Other genetic screening O233.1 Pregnant state, incidental O234.01 Normal first pregnancy, 1st tri O234.81 Other normal pregnancy, 1st tri		Family History Present: Y N If Yes, Indicate Relative: Sibling Parent Grandparent Aunt/Uncle Niece/Nephew Cousin Relative is: Affected by Or Carrier of Is patient or partner pregnant? Patient Partner Neither		
O09.529 Elderly multigravida, unsp tri		CS Commonly Utilized ICD Codes (Required)		
O28.3 Abnormal ultrasonic finding O28.5 Abnormal chromosomal and genetic finding O35.1XX0 (Suspected) chromosomal abnormality in fetus O35.1XX0 (Suspected) chromosomal abnormality in fetus	nomalies O	DE28.39 Other primary ovarian failure DE28.39 Other primary ovarian failure DE28.39 Other primary ovarian failure DE28.39 Encounter of female for testing for genetic disease carrier status for proceeding the process of the process of the musculoskeletal system and control of the process of the musculoskeletal system and control of the process of the musculoskeletal system and control of the process of the musculoskeletal system and control of the process of the musculoskeletal system and control of the process	ocreative mgmt	
For test and panel details, please visit www.SonicReproductiveHealth		284.81 Family history of carrier of genetic disease Other (please specify code):		

Sonic Healthcare **Reproductive Health**Prenatal





Non-Invasive Prenatal Screening ____

What is NIPS?

NIPS is a non-invasive blood test that screens for chromosome conditions in the pregnancy. These conditions are uncommon, do not usually run in the family, and can happen in any pregnancy. NIPS can be performed based on a single blood draw beginning at 10 weeks gestation. Collecting your blood sample for NIPS poses no threat to your baby.

What does NIPS test for?

Chromosome Conditions

- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)

Additional testing options are available, including fetal sex. Limitations and indications for screening for additional conditions should be discussed with your provider.

How accurate is NIPS?

NIPS is a screening test. While uncommon, some people may receive a positive result when the pregnancy is unaffected or a negative result when the pregnancy is affected. Testing for rarer conditions may negatively impact accuracy and increase the probability of a positive result being a false positive. 1 Any high-risk results should be confirmed with diagnostic laboratory testing.



Carrier Screening

What is a carrier?

A carrier is a person who has a genetic change, or mutation in their DNA, but, in most cases, does not have any associated health problems.

What does reproductive carrier screening test for?

Our test will help identify carriers for the main genetic disorders:

- Cystic Fibrosis (CF)
- Spinal Muscular Atrophy (SMA)
- Fragile X Syndrome (FX)*
- Hemoglobinopathy Screening (such as sickle cell anemia)
- Ashkenazi Jewish Panel
- Expanded Carrier Panel Options

Why test for these conditions?

CF, SMA, and FX are three of the most commonly inherited conditions. People are usually unaware that they are carriers and often do not have a history of these conditions in their family.

- CF is one of the most common life-limiting genetic conditions.
- SMA is the most common genetic cause of death in children under the age of two.
- FX is the most common form of inherited intellectual disability.

Results

Your results will be delivered to your provider, and he or she will discuss them with you. They will also be available to you in your SonicMyAccess™ patient portal.

Finding out about a genetic condition can raise important concerns around pregnancy planning and care. If it is determined you have a high-risk pregnancy, a licensed genetic counselor will reach out to you to provide education about what your results mean.*

*Patients must be enrolled with SonicMyAccess™ and confirm their enrollment with our genetic counseling service to have the benefit of this offering.



For patient resources and consent forms, please visit www.SonicReproductiveHealth.com

Important Test Information

MIPS is a screening test, therefore false-negative or false-positive results can occur. Carrier conditions including but not limited to blood transfusion, organ transplantation, bone marrow transplant, certain surgical procedures, stem cell therapy, malignancy, or genetic mosaicism can affect test accuracy. Pregnancy-related conditions such as fetal or placental genetic mosaicism, nonviable twin, or fetal demise can decrease test accuracy. There are exceptional and uncommon situations, which is why NIPS should be regarded as a screening test. There is a small, well-defined possibility that NIPS will not reflect the actual chromosome status of the fetus. A "high-probability" result should be confirmed by invasive genetic testing before taking irreversible steps in the management of the pregnancy. A "low-probability" should be continued by invalve genetic testing if there are other indicators of a fetal chromosome disorder. NIPS does not detect all genetic defects or non-genetic or structural birth defects. Conclusions about the fetal condition and pregnancy management decisions should not be solely based on the results of this screening test alone.

It is important to note that no pre-conception **carrier screen** is able to detect every mutation that might cause a genetic condition. The test does not detect every mutation that can cause cystic fibrosis, spinal muscular atrophy, and fragile X syndrome, or mutations in other genes responsible for other disorders. If no mutation is found, the risk of the patient being a carrier for these conditions is greatly reduced; however, the possibility cannot be eliminated. The patient's ethnicity may also affect carrier risk.

NIPS was developed and its performance characteristics determined by Sonic Reference Laboratory (SRL). It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes and should not be regarded as investigational or for research. SRL is qualified to perform high-complexity testing under the Clinical Laboratory Improvement Amendments (CLIA).

Copyright © 2024 Sonic Healthcare USA. Inc. All rights reserved. All of the information in this document is the property of Sonic Healthcare CASA, It may not be distributed, transmitted, reproduced, copied or displayed without the written permission of Sonic Healthcare USA. Sonic Healthcare USA, including its affiliates, does not dispense medical advice. The content in this marketing collateral is intended for informational purposes only and does not constitute legal, medical or any professional advice. Please consult your physician or a healthcare provider for additional information.

*Routine reproductive carrier screening for FX in male patients is not recommended

1. https://www.ajog.org/article/S0002-9378(17)31187-0/pdf